Syremis Therapeutics is advancing a neuropsychiatric pipeline grounded in clinically validated mechanisms, aiming to create best-in-class treatments for schizophrenia, major depressive disorder, bipolar depression and other psychiatric conditions. Its lead asset, ST-905, is a potent dual M1/M4 muscarinic receptor agonist now in Phase 1 trials and designed for once-daily oral dosing with the potential for a long-acting injectable formulation. A second program, ST-901, is a next-generation NMDA antagonist in IND-enabling studies and slated to enter Phase 1 next year to address depressive disorders. Both candidates originated at Clexio Biosciences before being spun out to Syremis. The company highlights the vast unmet need in schizophrenia, which affects more than 20 million people globally, and cites limitations in efficacy and tolerability of current therapies as its market entry point. Syremis is led by a seasoned team including co-founders Elisabeth Kogan (CEO), Elena Kagan (CDO), and Menashe Levy (CTO), with board members drawn from Dexcel Pharma, Third Rock Ventures, Bain Capital Life Sciences and other industry leaders. Its $165 million Series A financing provides the capital to advance both programs through clinical proof of concept. No commercial revenues or patient enrollment figures have been disclosed to date.

Total raised

$165M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025